Lina Elfaki: Anticoagulation Medications – A Critical Component of Patient Safety
Lina Elfaki, Senior clinical pharmacist, shared on LinkedIn:
“Anticoagulation Medications: A Critical Component of Patient Safety
Anticoagulation therapy plays a vital role in preventing and managing thromboembolic disorders across medical and surgical settings. From atrial fibrillation to post-operative care, the safe and effective use of anticoagulants requires careful clinical judgment and monitoring.
Key Anticoagulation Medications:
• Heparin & Low-Molecular-Weight Heparins (Enoxaparin)
• Vitamin K Antagonists (Warfarin)
• Direct Oral Anticoagulants (DOACs): Apixaban, Rivaroxaban, Dabigatran, Edoxaban
Clinical Focus Areas:
• Individualized dosing based on renal function and patient risk
• Monitoring for bleeding and thrombotic complications
• Managing drug–drug and drug–food interactions
• Peri-operative anticoagulation planning
• Patient education to ensure adherence and safety
Interdisciplinary collaboration—especially involving clinical pharmacists—enhances therapeutic outcomes and minimizes preventable adverse events.”
Stay updated on Hemostasis Today.
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs